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ABSTRACT 
Objective: The purpose of this study was to determine the effect of extra virgin olive oil (EVOO) and rice bran oil (RBO) on glycemic control and 
lipid profiles in patients with type-2 diabetes mellitus (T2DM). 
Methods: Ten patients with T2DM received 15 ml/day of EVOO or RBO. Levels of fasting blood glucose (FBG), postprandial blood glucose (PBG), total 
cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and triglycerides (TGs) were measured. 
RBO or EVOO was administered for 4 consecutive weeks. During a 2-week interval, the treatment was not administered. After this washout period, a 
crossover design was implemented by exchanging EVOO supplementation with RBO supplementation and vice versa for 4 consecutive weeks.  
Results: Changes in levels of FBG, PBG, TC, LDL-C, and TGs were not significantly different in the two groups. However, significantly decreased the 
levels of HDL-C were observed in both groups. 
Conclusion: RBO and EVOO had no significant influence on levels of FBG or PBG. 
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INTRODUCTION 
Diabetes mellitus (DM) is a major public-health problem worldwide. In 
2015, the American Diabetes Association stated that DM is a “collection 
of symptoms caused by an increase in blood glucose levels due to 
impaired secretion and insulin resistance or the effects of both” [1]. The 
International Diabetes Federation estimated that, in 2016,>415 million 
people worldwide experienced DM. It is estimated that by 2040, 
population of approximately 642 million will have DM symptoms [2]. 
The pathophysiology of type-2 diabetes mellitus (T2DM) is insulin 
resistance. The latter occurs due to the inability of insulin to 
stimulate glucose absorption in its target cells (muscle, fat) despite 
hyperinsulinemia [3, 4]. 
The main goal of ongoing nutritional therapy for DM is to maintain 
glucose levels in the blood close to normal to stop hyperglycemia 
and hyperlipidemia and lower the risk of complications. This goal 
can be achieved by eating a balanced diet (carbohydrates, 45%–
65%; fat, 20%–25%; protein 10%–15%) in accordance with the 
calorie and nutritional needs of each individual. Patients are 
expected to maintain regularity in terms of meal schedule as well as 
the type and amount of food [5, 6]. 
Olive oil is extracted from Olea europaea. This small tree is found in the 
Mediterranean, Asia, and Africa [7]. Olive oil consists of a glycerol 
fraction (90%–99% of olives) and a non-glycerol fraction (0.4%–5% of 
olives). The glycerol fraction of olive oil comprises 78% 
monosaturated fatty acids (MUFAs), 8% polyunsaturated fatty acids 
(PUFAs) and 12% saturated fatty acids (SFAs). The other 2% 
comprises>230 chemical compounds, including tocopherols, squalene, 
fatty alcohols, triterpene alcohol, phytosterols, polar pigments and 
hydrophilic compounds, especially polyphenols such as oleuropein 
and their metabolites hydroxytyrosol and tyrosol, which make up 
about 80% of the phenolic content of olive oil. These phenolic 
compounds are found in virgin oil and extra-virgin olive oil (EVOO). 
The olives are crushed mechanically, and the polyphenols within them 
disappear during distillation [8-10]. The phenolic compounds in olive 
oil are mainly hydroxytyrosol, tyrosol, and ligtroside [11, 12]. 
Rice bran oil (RBO) is extracted from the outer layer of rice grains. 
RBO contains saponifiable fractions and unsaponifiable fractions. 
The ionized fraction is in the form of triglycerides (TGs) and small 
amounts of diglycerides, monoglycerides, free fatty acids, waxes, 
glycolipids, and phospholipids. RBO contains 37% PUFAs, 38% 
MUFAs and 25% SFAs. A component of RBO is oryzanol, which is a 
mixture of steryl and other triterpenyl esters of ferulic acids. 
Oryzanol is absorbed by the intestine and reaches a maximum 
concentration in<1 h. It is metabolized in the liver to become a 
ferulate, which is then carried to the blood circulation. Other 
ingredients in RBO are phytosterols in the form of cholesterol, β-
sitosterol, and stigmasterol. The structure of phytosterol is similar to 
that of cholesterol but it contains ethyl groups in the branch chain. 
RBO is also rich in vitamin-E derivatives such as tocotrienols and 
tocopherols [13]. 
Studies conducted by the research teams of Rivellese [14], Carnevale 
[15], Lai [16], Devarajan [17], and Violi [18] have shown that RBO 
and EVOO can reduce blood sugar levels and control levels of 
cholesterol and TGs in T2DM patients. However, it is not known if 
RBO or EVOO is more effective in daily use, a question that we 
attempted to answer in the present study. 
MATERIALS AND METHODS 
Ethical approval of the study protocol 
The study protocol was approved by Medical Ethics Committee of 
the University of Indonesia (0407/UN2. F1/ETIK/2018). The 
present study has been registered at clinical. trial. gov 
(NCT03544411). 
Inclusion criteria 
The inclusion criteria were individuals suffering from T2DM: aged 
30–60 y; with a body mass index (BMI) of 20–30 kg/m2
Exclusion criteria 
; 
diagnosed<3 y; and taking anti-DM drugs. 
The exclusion criteria were individuals suffering from T2DM: with acute 
complications (hypoglycemia, diabetic ketoacidosis or hyperosmolar 
hyperglycemic non-ketotic syndrome); with chronic complications 
(coronary heart disease, gangrene, neuropathy, retinopathy); who were 
pregnant; taking cholesterol-lowering drugs, corticosteroids or other 
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drugs that affect fat metabolism; smoking>10 cigarettes/day; with 
glycated hemoglobin (HbA1C)>10%; taking a nutritional supplement 
containing phytosterol or other antioxidants; suffering from 
gastrointestinal, thyroid, cardiac, hepatic, or kidney disorders; suffering 
from cancer; who had suffered a stroke. 
Reasons for dropping out of the study 
Participants dropped out of the study because they: refused to 
continue the study; had a severe illness that necessitated hospital 
treatment during the study; consumed alcohol occasionally; had a 
level of compliance<80%; did not consume RBO or EVOO per 
protocol on three consecutive occasions. 
Study participants 
The study was carried out at FKUI Kayu Putih Family Clinic in Jakarta, 
Indonesia. The study was carried out from July to September 2018. 
Treatment 
We undertook a randomized, single-blind, crossover clinical trial to 
compare changes in levels of glucose, total cholesterol (TC), low-
density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C) and TGs for study participants treated with 15 
ml/day of EVOO or RBO. 
RBO or EVOO was administered for 4 consecutive weeks. During a 2-
week interval, treatment was not administered. After this washout 
period, a crossover design was implemented by exchanging EVOO 
supplementation with RBO supplementation and vice versa for 4 
consecutive weeks. 
Biochemical analyses 
Peripheral blood was taken from study participants and centrifuged 
at 1000 g for 10 min at room temperature to obtain serum. Serum 
samples were placed in Labgeo™ (Samsung, Seoul, South Korea) to 
obtain values for blood glucose, TC, LDL-C, HDL-C, and TGs within 
minutes. 
Statistical analyses 
Data were analyzed using SPSS v20 (IBM, Armonk, NY, USA) and the 
Data Analysis Tools within Office™ 2013 (Microsoft, Redmond, WA, 
USA). The Shapiro–Wilk test was undertaken to test for a normal 
distribution of values. Differences among groups were assessed by 
the paired t-test and Wilcoxon test. Values are the mean±SD. p<0.05 
was considered significant. 
RESULTS 
The study comprised 10 patients (9 females, 1 male) of mean age 
48.9 y. The mean BMI was 25.6 kg/m2
 
. Dietary analyses are shown in 
table 1 and show no significant difference in the intake of calories, 
carbohydrates, lipids or fiber before and after treatment. With 
regard to protein intake, there were significant differences before 
and after treatment with RBO (p = 0.005) and EVOO (p = 0.031). 
Table 1: Mean daily intake of energy, carbohydrates, proteins, lipids, and fiber of the RBO group and EVOO group at baseline and post-
intervention 
 RBO p EVOO p 
Energy intake, Kcal/day     




Carbohydrate intake, g     




Protein intake, g     




Fat intake, g     




Fiber intake, g     




Values are the mean±standard deviation or median, t: paired t-test, w: Wilcoxon test, p<0.05, significant. RBO, rice bran oil; EVOO, extra virgin olive oil. 
 
Fasting blood glucose (FBG) levels 
FBG levels were not significantly different before and after 
treatment with RBO and EVOO as shown in table 2. There was a 
tendency of decreasing FBG levels. FBG levels before treatment was 
198.9±54.7 mg/dl and after treatment was 192.5±57.3 mg/dl with 
RBO. After giving EVOO, the FBG level was 191.5±50.7 mg/dl. 
 
Table 2: Levels of fasting blood glucose and postprandial blood glucose in the RBO group and EVOO group at baseline and post-intervention 
 RBO p EVOO P 
Fasting blood glucose     
Baseline 198.9±54.7 0.731  198.9±54.7  t 0.674
Post-intervention 
t 
 192.5±57.3   191.5±50.7  
Postprandial blood glucose     
Baseline 276.2±93.9 0.688 276.2±93.9 t 0.669
Post-intervention 
t 
 264.4±80.0 262.4±95.3  
Values are the mean±standard deviation or median, t: paired t-test, w: Wilcoxon test, p<0.05, significant. RBO, rice bran oil; EVOO, extra virgin olive oil. 
 
Postprandial blood glucose (PBG) levels 
PBG levels were not significantly different before and after 
treatment as shown in table 2. The PBG level before treatment was 
276.2±93.9 mg/dl. Upon treatment with RBO, this changed to 
264.4±80.0 mg/dl; upon treatment with EVOO, it changed to 
262.4±95.3 mg/dl. After treatment with RBO or EVOO, the mean 
level of FBG and PBG was high. These results suggested that, 
although there was a downward trend in levels of FBG and PBG, 
there was no improvement in clinical status. 
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With regard to TC levels, administration of RBO and EVOO did not 
result in a significant difference as shown in table 3. The baseline 
value was 177.0±54.7 mg/dl. Upon treatment with RBO, it changed 
to 187.1±27.8 mg/dl; upon treatment with EVOO, it changed to 
194.8 mg/dl. Although there was a tendency to increase, TC levels 
remained within the normal threshold. 
 
Table 3: Lipid profiles of the RBO group and EVOO group at baseline and post-intervention 
 RBO p EVOO P 
TC, mg/dl     
 Baseline 177.0±26.7 0.288 177.0±26.7 t 0.169
Post-intervention 
w 
187.1±27.8  194.8(163.264)  
LDL-C, mg/dl     




HDL-C, mg/dl     
 Baseline 58.9±11.5 0.012 58.9±11.5 w 0.025
 Post-intervention 
t 
52.8 (46.63) 54.7±10.9 
Triglycerides, mg/dl     




Values are the mean±standard deviation or median, t: paired t-test, w: Wilcoxon test, p<0.05, significant. RBO, rice bran oil; EVOO, extra virgin olive oil. 
 
In regard to LDL-C levels, administration of RBO and EVOO did not 
result in a significant difference. The baseline value was 97.1±21.5 
mg/dl. Upon treatment with RBO, it changed to 109.7±25.8 mg/dl; 
upon treatment with EVOO, it changed to 116.7 mg/dl. 
There were significant differences in HDL-C levels in both groups 
before and after treatment. The baseline value was 58.9±11.5 mg/dl. 
Upon treatment with RBO, it changed to 52.8 mg/dl; after treatment 
with EVOO, it changed to 54.7±10.9 mg/dl. Nevertheless, these 
decreases in HDL-C levels were in the normal range. 
For TGs, there were no significant differences before and after 
treatment. The baseline value was 106.3±31.5 mg/dl. Upon 
treatment with RBO, it changed to 122.1±37.9 mg/dl; after 
treatment with EVOO, it changed to 117.1±35.2 mg/dl. 
DISCUSSION 
Changes in blood glucose levels upon RBO administration in the present 
study were not significantly different from those recorded in other 
studies. In research conducted by Devarajan and colleagues using a 
mixture of RBO with sesame seeds in a large study for 8 w, changes in 
blood glucose levels showed a significant change (p<0.001) [17]. 
Decreases in blood glucose levels after EVOO administration in the 
present study are in accordance with those documented by 
Carnevale and co-workers, as well as with large studies in which 
olive oil was added to a Mediterranean diet [15, 19, 20].  
MUFA content in RBO and EVOO can change the composition of fatty 
acids in target cell membranes so that the function of insulin 
receptors is affected. MUFA causes changes in the composition of cell 
membranes so that they are richer in cis-type fatty acids. This 
alteration of composition results in the formation of more spaces 
between membrane head groups so that they are more broadly 
hydrophilic. This change increases the fluidity of cell membranes 
and activates key receptor proteins (G proteins, protein kinase Cα 
subunits), which can reach the membrane surface readily and 
increase signal sensitivity. MUFAs also improve the entero-insular 
axis by increasing the secretion and activity of glucagon-like peptide 
(GLP)-1 and gastric inhibitory polypeptide. This increase can 
increase the secretion and biosynthesis of insulin. In addition, GLP-1 
can reduce glucagon levels, which makes GLP-1 effective as 
nutritional therapy in DM. MUFAs also reduce damage and trigger 
neogenesis of pancreatic beta cells. The main mechanism that causes 
damage to pancreatic beta cells is toxicity to glucose and lipids [21]. 
The results of the present study are contrary to those of Lai and 
colleagues showing a decrease in TC levels upon RBO administration 
[16]. However, our data for EVOO administration are in accordance with 
those of Carnevale and colleagues [15]. The study by Lai and colleagues 
employed a different method by giving “modified” RBO in the form of 
milk with a larger dose (18 g of RBO) and longer time (5 w) compared 
with our study. The decrease in TC levels due to RBO administration 
occurs due to the γ-oryzanol content in RBO, which can inhibit levels of 
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase and 
increases expression of cytochrome P450 (CYP)7A1. Phytosterols found 
in RBO and EVOO can reduce TC levels. 
Our results for RBO are different from those of Lai et al., who 
showed a significant decrease in LDL-C levels after RBO treatment. 
The decrease in LDL-C levels is influenced by the γ-oryzanol and 
phytosterol in RBO, which increase expression of hepatic LDL-C 
receptors so as to increase cholesterol catabolism. γ-oryzanol can 
also inhibit levels of HMG-CoA reductase and reduce cholesterol 
levels in the liver by increasing expression of LDL-C receptors in the 
liver and blood [16].  
Devarajan and co-workers found a significant increase in HDL-C 
levels at 8 w in 300 newly diagnosed DM patients given a mixture of 
EVOO and sesame seeds [17]. Previous studies on EVOO showed no 
significant changes in olive oil [15]. Increased HDL-C levels in RBO 
and EVOO could be due to the activity of the antioxidant phytosterol 
and vitamin E. In RBO, γ-oryzanol acts as an antioxidant [13, 23, 24]. 
Our results do not correspond with studies showing significantly 
decreased levels of TGs [14, 15, 17, 25]. Kuriyan and colleagues used 
RBO for daily cooking so that it did not change the proportion of 
daily fat intake. That method was different to our method, whereby 
RBO was consumed directly. Hence, fat consumption from oil was 
greater and the proportion of fat intake was greater, as can be seen 
from analyses of food intake after treatment [25]. 
An additional benefit of lowering levels of FBG and PBG can be 
achieved using RBO and EVOO. Thus, we recommend using RBO and 
EVOO for cooking, dressing salads or frying food. 
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